The future of Janus kinase inhibitors in inflammatory Bowel disease

Journal of Crohn's and Colitis

Volumn 11, Issue 7, 2017, Pages 885-893

  De Vries, L C S ^a   Wildenberg, M E ^a   De Jonge, W J ^a   D'Haens, Geert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Crohn's disease; Filgotinib; Kinase inhibitors; Tofacitinib; Ulcerative colitis

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; FILGOTINIB; GLPG 063; GSK 2586184; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; JNJ 54781532; SOLCITINIB; STAT PROTEIN; TOFACITINIB; UNCLASSIFIED DRUG; UPADACITINIB; CYTOKINE; JANUS KINASE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ABSCESS; ANEMIA; BINDING SITE; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATORY BOWEL DISEASE; JAK-STAT SIGNALING; JAK2 GENE; JAK3 GENE; LIVER TOXICITY; LYMPHOCYTOPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REMISSION; REVIEW; RHINOPHARYNGITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TH17 CELL; TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS; ULCERATIVE COLITIS; ANIMAL; GENETICS; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; JANUS KINASE INHIBITORS; JANUS KINASES; MUTATION; PIPERIDINES; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85028968128     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjx003     Document Type: Review

References (71)

1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-19.
2. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012;380:1590-605.
3. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.
4. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61:918-32.
5. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
6. Filippi J, Allen PB, Hébuterne X, Peyrin-Biroulet L. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets 2011;12:1440-7.
7. Lam MC, Bressler B. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. Immunotherapy 2014;6:963-71.
8. Feagan BG, Sandborn WJ, Gasink C, et al.; UNITI-IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016;375:1946-60.
9. Papp KA, Krueger JG, Feldman SR, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 2016;74:841-50.
10. Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2016;75:1293-301.
11. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014;20:1043-9.
12. Sandborn WJ, Sands BE, D'Haens G, et al. Presentation OP019 efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials. Eleventh Congress of the European Crohn's and Colitis Organisation, March 16-19, 2016, RAI Amsterdam, The Netherlands.
13. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72[Suppl 2]:ii111-5.
14. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 2012;12:464-70.
15. Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A 1989;86:1603-7.
16. Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zürcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferaserelated catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991;11:2057-65.
17. Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994;370:151-3.
18. Rane SG, Reddy EP. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994;9:2415-23.
19. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14.
20. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5.
21. Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 2015;194:21-7.
22. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012;36:542-50.
23. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86.
24. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169-78.
25. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4.
26. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005;5:521-31.
27. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
28. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64.
29. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013;121:2402-14.
30. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009;58:1152-67.
31. O'Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009;10:603-9.
32. Hueber W, Sands BE, Lewitzky S, et al.; Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-700.
33. Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderateto-severe Crohn's disease. Am J Gastroenterol 2016;111:1599-607.
34. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib [CP-690, 550]. J Immunol 2011;186:4234-43.
35. Hainzl E, Stockinger S, Rauch I, et al. Intestinal epithelial cell tyrosine kinase 2 transduces IL-22 signals to protect from acute colitis. J Immunol 2015;195:5011-24.
36. Li Z, Gakovic M, Ragimbeau J, et al. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. J Immunol 2013;190:2335-44.
37. Can G, Tezel A, Gürkan H, et al. Tyrosine kinase-2 gene polymorphisms are associated with ulcerative colitis and Crohn's disease in Turkish population. Clin Res Hepatol Gastroenterol 2015;39:489-98.
38. Hedl M, Proctor DD, Abraham C. JAK2 disease-risk variants are gain of function and JAK signaling threshold determines innate receptorinduced proinflammatory cytokine secretion in macrophages. J Immunol 2016;197:3695-704.
39. Jostins L, Ripke S, Weersma RK, et al.; International IBD Genetics Consortium [IIBDGC]. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
40. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
41. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93:373-83.
42. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010;115:3589-97.
43. Baxter EJ, Scott LM, Campbell PJ, et al.; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
44. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science 1995;270:800-2.
45. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 2012;36:515-28.
46. Notarangelo LD, Mella P, Jones A, et al. Mutations in severe combined immune deficiency [SCID] due to JAK3 deficiency. Hum Mutat 2001;18:255-63.
47. Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000;13:561-71.
48. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007;448:1058-62.
49. Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012;160:1055-7.
50. Kreins AY, Ciancanelli MJ, Okada S, et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 2015;212:1641-62.
51. Piscianz E, Valencic E, Cuzzoni E, et al. Fate of lymphocytes after withdrawal of tofacitinib treatment. PLoS One 2014;9:e85463.
52. Yoshida H, Kimura A, Fukaya T, et al. Low dose CP-690, 550 [tofacitinib], a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochem Biophys Res Commun 2012;418:234-40.
53. Shen F, Brassil P, Hegde S, Beattie D. Poster presentation. P036 Colontargeted delivery of tofacitinib inhibits oxazolone-induced colitis in mice, despite low systemic exposure. Eleventh Congress of the European Crohn's and Colitis Organisation, March 16-19, 2016, RAI Amsterdam, The Netherlands.
54. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib [the FITZROY study]: results from a phase 2, double-blind, randomised, placebocontrolled trial. Lancet, published online Dec 14 2016. http://dx.doi. org/10.1016/S0140-6736[16]32538-7.
55. Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013;191:3568-77.
56. Uckun FM, Tibbles H, Ozer Z, Qazi S, Vassilev A. Anti-inflammatory activity profile of JANEX-1 in preclinical animal models. Bioorg Med Chem 2008;16:1287-98.
57. Mishra J, Verma RK, Alpini G, Meng F, Kumar N. Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis. J Biol Chem 2013;288:31795-806.
58. Ishizaki M, Akimoto T, Muromoto R, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol 2011;187:181-9.
59. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:1485-93.
60. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976;70:439-44.
61. Panés J, Sandborn WJ, Schreiber S, et al. Presentation OP021. Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohn's disease: results of a Phase 2b randomised placebocontrolled trial. Eleventh Congress of the European Crohn's and Colitis Organisation. March 1619, 2016, RAI Amsterdam, The Netherlands.
62. D'Haens G, Pannaccione R, Higgins PDR, et al. Presentation OP022. Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-to-severe Crohn's disease: results of a Phase 2b randomised placebo-controlled trial. Eleventh Congress of the European Crohn's and Colitis Organisation, March 16-19, 2016, RAI Amsterdam, The Netherlands.
63. Sandborn WJ, Ghosh S, Panes J, et al.; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24.
64. De Vries LCS, Hilbers-van Leeuwen FWM, Verseijden C, et al. Poster presentation P601. The efficacy of GSK2586184, a novel selective Janus kinase 1 inhibitor, in patients with moderate to severely active ulcerative colitis. Eleventh Congress of the European Crohn's and Colitis Organisation, March 16-19, 2016, RAI Amsterdam, The Netherlands.
65. Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015;17:362.
66. Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2015;75:1133-8.
67. Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis vs healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015;67:616-25.
68. Maini RN, Taylor PC, Szechinski J, et al.; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
69. Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med 2013;210:205-8.
70. Pfizer Advisory Committee Meeting. Tofacitinib for Treatment of Rheumatoid Arthritis [NDA 203214]. May 9, 2012 edition. http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960. Accessed February 14, 2014.
71. Sandborn WJ, Feagan BG, Wolf DC, et al.; TOUCHSTONE Study Group. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 2016;374:1754-62.